Skip to main content

Table 1 First- and second-line antiretroviral therapy regimens in use in TREAT Asia and IeDEA Southern Africa

From: A biregional survey and review of first-line treatment failure and second-line pediatric antiretroviral access and use in Asia and southern Africa

Site

Country

Nationally recommended paediatric first-line ART regimen*

Nationally recommended paediatric second-line ART regimen after NNRTI

Most commonly used second-line regimen in current site cohort

TREAT Asia

    

National Center for HIV, AIDS, Dermatology, and Sexually Transmitted Infections

Cambodia

d4T or AZT+3TC+NVP or EFV

If NNRTI exposure:

d4T+3TC+LPV/r

ABC+ ddI+LPV/r

ABC+3TC+LPV/r

Beijing Ditan Hospital

China

d4T or AZT+3TC+NVP or EFV

If NNRTI exposure:

AZT+3TC+LPV/r

ABC+3TC+AZT+LPV/r

ABC+3TC+AZT+LPV/r

YRG Centre for AIDS Research and Education

India

d4T or AZT+3TC+NVP or EFV

ABC+ddI+3TC+LPV/r

TDF or ddI+3TC or FTC+LPV/r

Cipto Mangunkusumo Hospital

Indonesia

d4T or AZT+3TC+NVP or EFV

ddI+3TC+LPV/r

ddI+3TC+LPV/r

Hospital Kuala Lumpur

Malaysia

<3yr:

AZT+3TC or ddI+NVP

≥3yr:

AZT+3TC or ddI+EFV

2 new NRTI+LPV/r

d4T+3TC+LPV/r

Hospital Likas

Malaysia

<3yr:

AZT+3TC or ddI+NVP

≥3yr:

AZT+3TC or ddI+EFV

2 new NRTI+LPV/r

d4T+ddI+LPV/r

Hospital Penang

Malaysia

<3yr:

AZT+3TC or ddI+NVP

≥3yr:

AZT+3TC or ddI+EFV

2 new NRTI+LPV/r

--

Hospital Raja Perempuan Zainab

Malaysia

<3yr:

AZT+3TC or ddI+NVP

≥3yr:

AZT+3TC or ddI+EFV

2 new NRTI+LPV/r

d4T+ddI+LPV/r

Chiang Mai University Medical Centre

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+3TC+LPV/r

Chiang Rai Regional Hospital

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+3TC+LPV/r

HIV-NAT

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+3TC+LPV/r

Khon Kaen University Medical Centre

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+ddI+LPV/r

Siriraj Hospital

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+ddI+LPV/r

Children's Hospital 1

Vietnam

d4T+3TC+NVP

ABC+ddI+LPV/r

--

Children's Hospital 2

Vietnam

d4T+3TC+NVP

ABC+ddI+LPV/r

ABC+ddI+LPV/r

National Hospital of Paediatrics

Vietnam

d4T+3TC+NVP

ABC+ddI+LPV/r

ABC+ddI+LPV/r

IeDEA Southern Africa

    

Lighthouse Clinic

Malawi

d4T+3TC+NVP

ABC+ddI+LPV/r

AZT+3TC+LPV/r

Paediatric Day Hospital, Maputo

Mozambique

d4T or AZT+3TC+NVP or EFV

If NNRTI exposure:

d4T or AZT+3TC+LPV/r

ABC+ddI+LPV/r

None

Rahima Moosa Mother and Child Hospital

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

ABC+3TC+LPV/r

Gugulethu Community Health Centre

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+EFV or LPV/r ABC+3TC+LPV/r

Harriet Shezi Clinic

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+LPV/r

Khayelitsha Community Health Centre

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+LPV/r

McCord Hospital

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+LPV/r

Red Cross Children's Hospital

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+EFV

Tygerberg Hospital

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+LPV/r

Newlands Clinic

Zimbabwe

AZT+3TC+NVP

ddI+3TC+LPV/r

d4T+3TC+NVP

  1. *Content reflects current recommendations at the time of the survey. WHO first-line regimen recommendations at the time of the survey included two NRTIs with one NNRTI or two NRTIs with one PI/r if the infant had previous NNRTI exposure [10,17]; second-line regimen recommendations after NNRTI failure included two NRTIs with one PI/r or unboosted nelfinavir in limited circumstances.
  2. d4T - stavudine; AZT - zidovudine; 3TC - lamivudine; NVP - nevirapine; EFV - efavirenz; ABC - abacavir; ddI - didanosine; LPV/r - ritonavir-boosted lopinavir; TDF - tenofovir; FTC - emtricitabine; NRTI - nucleoside reverse transcriptase inhibitor; NNRTI - non-nucleoside reverse transcriptase inhibitor.